Distinct representation of muscle weakness in QMG and MG-ADL - Authors' reply

Affiliations

¹ Department of Neurology, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: howardj@neurology.unc.edu.
² Alexion Pharmaceuticals, New Haven, CT, USA.

Comment

James F Howard Jr et al. Lancet Neurol. 2018 Mar.

. 2018 Mar;17(3):205-206.

doi: 10.1016/S1474-4422(18)30036-X.

¹ Department of Neurology, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: howardj@neurology.unc.edu.
² Alexion Pharmaceuticals, New Haven, CT, USA.

No abstract available

Comment on

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Distinct representation of muscle weakness in QMG and MG-ADL.
de Meel RHP, Verschuuren JJGM, Tannemaat MR. de Meel RHP, et al. Lancet Neurol. 2018 Mar;17(3):204-205. doi: 10.1016/S1474-4422(18)30037-1. Lancet Neurol. 2018. PMID: 29452679 No abstract available.